KR20220098938A - Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy - Google Patents

Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy Download PDF

Info

Publication number
KR20220098938A
KR20220098938A KR1020210000852A KR20210000852A KR20220098938A KR 20220098938 A KR20220098938 A KR 20220098938A KR 1020210000852 A KR1020210000852 A KR 1020210000852A KR 20210000852 A KR20210000852 A KR 20210000852A KR 20220098938 A KR20220098938 A KR 20220098938A
Authority
KR
South Korea
Prior art keywords
skin
weight
composition
external application
extract
Prior art date
Application number
KR1020210000852A
Other languages
Korean (ko)
Inventor
조용국
Original Assignee
엘리펀 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘리펀 주식회사 filed Critical 엘리펀 주식회사
Priority to KR1020210000852A priority Critical patent/KR20220098938A/en
Publication of KR20220098938A publication Critical patent/KR20220098938A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13Coniferophyta (gymnosperms)
    • A61K36/14Cupressaceae (Cypress family), e.g. juniper or cypress
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention provides a composition for skin external application comprising, as an active component, the composition for skin external application containing a distilled extract of a rare earth composite bio-mineral material as an active component, wherein the composition for skin external application according to the above configuration has a skin condition improving activity, particularly has an excellent improvement effect on allergies and atopy, which are the causes of skin troubles.

Description

희토류 복합바이오광물질의 증류추출액을 활성성분으로 함유하는 피부외용제 조성물{SKIN EXTERNAL COMPOSITION COMPRISING DISTILLED EXTRACT OF RARE EARTH COMPLEXBIOMINERAL FOR ALLEVIATING SKIN ALLERGY}Composition for external application for skin containing a distillate extract of rare earth complex bio-mineral as an active ingredient

본 발명은 피부외용제 조성물에 관한 것으로, 보다 상세하게는 피부상태개선활성, 특히 피부트러블의 원인이 되는 알러지, 아토피에 대한 개선효과가 탁월한 희토류 복합바이오광물질의 증류추출액을 활성성분으로 함유하는 피부외용제 조성물에 관한 것이다.The present invention relates to a composition for external application for skin, and more particularly, to an external preparation for skin containing, as an active ingredient, a distillate extract of rare earth complex bio-mineral, which has excellent skin condition improvement activity, in particular, an improvement effect on allergies and atopy, which are the causes of skin troubles. to the composition.

아토피피부염은 호전과 악화를 반복하는 만성 재발성 습진 질환으로 최근 점점 증가하는 추세이며, 우리나라의 경우에도 아토피피부염을 진단받은 초등학생의 수가 매년 증가하고 있고, 중증 환자의 비율도 점차 증가하고 있는 것으로 나타났다. 또한 18세에 이르러서도 8.5%의 유병률을 보이는 등 현재 주요한 국민 보건문제로 대두되고 있다.Atopic dermatitis is a chronic recurrent eczema disease that repeats improvement and exacerbation, and it is on the rise in recent years. . In addition, it is emerging as a major public health problem, with a prevalence of 8.5% even at the age of 18.

아토피 피부염 1기라고 할 수 있는 유아기 아토피 피부염은 생후 3개월부터 2세 사이 양 볼에 소양성 홍반으로 시작하여, 악화되면 미세한 수포, 삼출, 습윤성 가피, 농포 형성 등의 증상이 생긴다. 특히, 병발부위는 양볼, 머리, 목, 이마, 손목, 팔 다리의 측부, 둔부 등에 주로 발생한다. 또한, 습윤형, 지루형, 건조형의 3가지 양상을 지니고 있으며, 상기 습윤형이 유아기 아토피 피부염에서 가장 흔한 것이며, 지루형은 지루성 경향과 동반, 전신적 박탈성 홍피증이 발생한다. 건조형은 심한 피부 건조증을 동반한다.Infantile atopic dermatitis, which can be called the first stage of atopic dermatitis, starts with itchy erythema on both cheeks between 3 months and 2 years of age, and when it worsens, symptoms such as microvesicles, exudation, wet scab, and pustule formation occur. In particular, the affected area mainly occurs on the cheeks, head, neck, forehead, wrist, side of arms and legs, buttocks, etc. In addition, it has three aspects: wet type, seborrheic type, and dry type. The wet type is the most common in atopic dermatitis in infancy, and the seborrheic type is accompanied by seborrheic tendency and systemic exfoliative erythroderma occurs. The dry type is accompanied by severe dry skin.

아토피 피부염 2기라고 할 수 있는 소아기 아토피 피부염은 2세에서 10세 사이에 주로 발생하며, 유아기 습진보다 다소 경미한 급성 병변(진물이 적고 보다 건조한 병변, 가피)이 발생한다. 주요 병발부위는 전주부, 슬와부, 굴측부, 손목, 안검, 안면, 목주위 등이다. 상기 소아기 아토피 피부염의 기본 병변은 건조하고 약간 융기된 편평구진으로 이들이 융합하여 태선(lichenification)양상, 대부분 표피 박리(excoriation)가 있다.Childhood atopic dermatitis, which can be called the second stage of atopic dermatitis, occurs mainly between the ages of 2 and 10 years, and acute lesions (less oozing and dry lesions, scabs) that are slightly milder than those of infancy eczema occur. The main affected areas are the anterior periphery, the popliteal region, the flexor part, the wrist, the eyelids, the face, and the neck. The basic lesion of the childhood atopic dermatitis is dry, slightly raised squamous papules, which fuse to form lichenification, mostly epidermal excoriation.

아토피 피부염 3기라고 할 수 있는 사춘기 및 성인 아토피 피부염은 10세 이상에서 주로 나타나며, 국한성 홍반, 인설, 구진 또는 수포성반을 형성하거나 과색소 침착된 태선화반(lichenoid patches)으로 나타난다. 주요 병발부위는 전주부, 슬와부, 굴측부, 목, 이마, 눈 주위, 손, 손목 등이다.Atopic dermatitis stage 3 Atopic dermatitis in adolescents and adults occurs mainly in those aged 10 years or older, and is characterized by the formation of localized erythema, scales, papules, or bullous plaques or as hyperpigmented lichenoid patches. The main affected areas are the anterior periphery, the popliteal region, the flexor part, the neck, forehead, around the eyes, hands, and wrists.

이러한 아토피성 피부염 증상에 현재에는 대체로 항소양제, 항균제, 면역조절제 및 스테로이드 등의 소재를 사용하고 있다. 그러나 이러한 아토피 소재는 장시간 투여에 따른 내성 발생, 증상완화와 재발의 반복 및 일부 치료제의 부작용 등이 발생하는 문제점이 있다.Currently, materials such as antipruritic agents, antibacterial agents, immunomodulators and steroids are generally used for these atopic dermatitis symptoms. However, these atopic materials have problems such as generation of resistance due to long-term administration, repetition of symptom relief and recurrence, and side effects of some therapeutic agents.

본 발명은 상기한 바와 같이 종래기술이 가지는 문제를 해결하기 위해 제안된 것으로, 그 목적은 피부상태개선활성, 특히 피부트러블의 원인이 되는 알러지, 아토피에 대한 개선효과가 탁월한 피부외용제 조성물을 제공함에 있다.The present invention has been proposed to solve the problems of the prior art as described above, and its object is to provide a composition for external application for skin excellent in skin condition improvement activity, in particular, an improvement effect on allergies and atopic dermatitis that cause skin troubles. have.

상기한 바와 같은 본 발명의 기술적 과제는 다음과 같은 수단에 의해 달성되어진다.The technical problem of the present invention as described above is achieved by the following means.

(1) 희토류 복합바이오광물질의 증류추출액을 활성성분으로 함유하는 피부외용제 조성물.(1) A composition for external application for skin containing a distillate extract of rare earth complex bio-minerals as an active ingredient.

(2) 상기 (1)에 있어서,(2) in (1) above,

상기 희토류 복합바이오광물질은 F 0.1~0.2중량%, Na2O 0.1~0.2중량%, MgO 0.08~0.09중량%, Al2O3 34.0~35.0중량%, SiO2 58.0~59.0중량%, P2O5 0.04~0.05중량%, SO3 0.01~0.02중량%, Cl 0.003~0.004중량%, K2O 2.8~2.9중량%, CaO 0.008~0.009중량%, TiO2 1.5~1.6중량%, Cr2O3 0.01~0.02중량%, MnO 0.01~0.02중량%, Fe2O3 1.0~2.0중량%, NiO 0.005~0.006중량%, CuO 0.002~0.003중량%, Ga2O5 0.006~0.007중량%, SrO 0.02~0.03중량%, Y2O3 0.005~0.006중량%, ZrO2 0.02~0.03중량%, BaO 0.05~0.06중량%, ReO2 0.006~0.007중량%, PbO 0.004~0.005중량%, TbO2 0.002~0.003중량%, Pa 0.02~0.03중량%를 포함하는 것을 특징으로 하는 피부외용제 조성물.The rare earth composite bio-mineral material is F 0.1 to 0.2 wt%, Na 2 O 0.1 to 0.2 wt%, MgO 0.08 to 0.09 wt%, Al 2 O 3 34.0 to 35.0 wt%, SiO 2 58.0 to 59.0 wt%, P 2 O 5 0.04~0.05 wt%, SO 3 0.01~0.02 wt%, Cl 0.003~0.004 wt%, K 2 O 2.8~2.9 wt%, CaO 0.008~0.009 wt%, TiO 2 1.5~1.6 wt%, Cr 2 O 3 0.01 to 0.02 wt%, MnO 0.01 to 0.02 wt%, Fe 2 O 3 1.0 to 2.0 wt%, NiO 0.005 to 0.006 wt%, CuO 0.002 to 0.003 wt%, Ga 2 O 5 0.006 to 0.007 wt%, SrO 0.02 to 0.03 wt%, Y 2 O 3 0.005 to 0.006 wt%, ZrO 2 0.02 to 0.03 wt%, BaO 0.05 to 0.06 wt%, ReO 2 0.006 to 0.007 wt%, PbO 0.004 to 0.005 wt%, TbO 2 0.002 to 0.003 wt% %, Pa composition for external application for skin, characterized in that it comprises 0.02 to 0.03% by weight.

(3) 상기 (1)에 있어서, 상기 증류추출액은,(3) In the above (1), the distillate extract,

상기 희토류 복합바이오광물질을 물과 함께 증류기에 넣고 온도 110~130℃로 1~10시간 동안 가열한 후, 증류시켜 얻어진 것을 특징으로 하는 피부외용제 조성물.The composition for external application for skin, characterized in that it is obtained by putting the rare earth complex biomineral together with water in a distiller, heating it at a temperature of 110 to 130° C. for 1 to 10 hours, and then distilling it.

(4) 상기 (1)에 있어서,(4) in (1) above,

상기 증류추출액과 함께 어성초, 측백잎, 모려분, 유근피, 백선피, 및 지실의 증류추출액을 더 포함하는 것을 특징으로 하는 피부외용제 조성물.The composition for external application for skin, characterized in that it further comprises a distillate extract of eoseongcho, chrysanthemum leaves, moryu powder, eugeunpi, baekseonpi, and lichen together with the distillate extract.

(5) 상기 (4)에 있어서,(5) in (4) above,

상기 증류추출액 10~70중량%, 어성초 1~30 중량%, 측백잎 1~20중량%, 모려분 1~10중량%, 유근피 1~10중량%, 백선피 1~10중량%, 및 지실 1~10중량%를 증류기에 투입하여 증류시켜 얻어진 피부개선추출액을 포함하는 것을 특징으로 하는 피부외용제 조성물.10 to 70% by weight of the distillation extract, 1 to 30% by weight of Eoseongcho, 1 to 20% by weight of chrysanthemum leaves, 1 to 10% by weight of mulberry flour, 1 to 10% by weight of Yugeun skin, 1 to 10% by weight of white sagebrush, and 1 A composition for external application for skin, characterized in that it contains a skin improvement extract obtained by distilling by distilling ~10% by weight.

(6) 상기 (1) 내지 (4) 중 선택된 어느 하나에 있어서,(6) in any one selected from (1) to (4),

피부외용제는 아토피 치료용 조성물인 것을 특징으로 하는 피부외용제 조성물.The composition for external application for skin is a composition for the treatment of atopic dermatitis.

본 발명에 의한 피부외용제 조성물은 피부상태개선활성, 특히 피부트러블의 원인이 되는 알러지, 아토피에 대한 개선효과가 탁월하다. The composition for external application for skin according to the present invention is excellent in skin condition improvement activity, in particular, the improvement effect on allergies and atopy that cause skin troubles.

본 발명에 따른 피부외용제는 희토류 복합바이오광물질의 증류추출액을 활성성분으로 포함한다.The external preparation for skin according to the present invention contains the distillate extract of rare earth complex bio-minerals as an active ingredient.

본 발명의 상기 희토류 복합바이오광물질은 바람직하게는 F 0.1~0.2중량%, Na2O 0.1~0.2중량%, MgO 0.08~0.09중량%, Al2O3 34.0~35.0중량%, SiO2 58.0~59.0중량%, P2O5 0.04~0.05중량%, SO3 0.01~0.02중량%, Cl 0.003~0.004중량%, K2O 2.8~2.9중량%, CaO 0.008~0.009중량%, TiO2 1.5~1.6중량%, Cr2O3 0.01~0.02중량%, MnO 0.01~0.02중량%, Fe2O3 1.0~2.0중량%, NiO 0.005~0.006중량%, CuO 0.002~0.003중량%, Ga2O5 0.006~0.007중량%, SrO 0.02~0.03중량%, Y2O3 0.005~0.006중량%, ZrO2 0.02~0.03중량%, BaO 0.05~0.06중량%, ReO2 0.006~0.007중량%, PbO 0.004~0.005중량%, TbO2 0.002~0.003중량%, Pa 0.02~0.03중량%를 포함한다.The rare earth composite biomineral of the present invention is preferably F 0.1 to 0.2 wt%, Na 2 O 0.1 to 0.2 wt%, MgO 0.08 to 0.09 wt%, Al 2 O 3 34.0 to 35.0 wt%, SiO 2 58.0 to 59.0 wt%, P 2 O 5 0.04 to 0.05 wt%, SO 3 0.01 to 0.02 wt%, Cl 0.003 to 0.004 wt%, K 2 O 2.8 to 2.9 wt%, CaO 0.008 to 0.009 wt%, TiO 2 1.5 to 1.6 wt% %, Cr 2 O 3 0.01~0.02 wt%, MnO 0.01~0.02 wt%, Fe 2 O 3 1.0~2.0 wt%, NiO 0.005~0.006 wt%, CuO 0.002~0.003 wt%, Ga 2 O 5 0.006~0.007 wt%, SrO 0.02~0.03 wt%, Y 2 O 3 0.005~0.006 wt%, ZrO 2 0.02~0.03 wt%, BaO 0.05~0.06 wt%, ReO 2 0.006~0.007 wt%, PbO 0.004~0.005 wt%, TbO 2 0.002 to 0.003% by weight, including 0.02 to 0.03% by weight of Pa.

본 발명의 상기 희토류 복합바이오광물질은 보다 바람직하게는 태백 예낭광산에서 채취한 하기 표 1 성분조성 분포를 갖는 것으로 한다.The rare earth composite bio-mineral material of the present invention more preferably has the composition distribution in Table 1 below taken from the Yenang Mine in Taebaek.

성분ingredient 중량%weight% FF 0.13580.1358 Na2ONa 2 O 0.11940.1194 MgOMgO 0.08200.0820 Al2O3 Al 2 O 3 34.773934.7739 SiO2 SiO 2 58.557658.5576 P2O5 P 2 O 5 0.04270.0427 SO3 SO 3 0.01050.0105 ClCl 0.00340.0034 K2OK 2 O 2.86952.8695 CaOCaO 0.00800.0080 TiO2 TiO 2 1.50241.5024 Cr2O3 Cr 2 O 3 0.01530.0153 MnOMnO 0.01460.0146 Fe2O3 Fe 2 O 3 1.70341.7034 NiONiO 0.00550.0055 CuOCuO 0.00250.0025 Ga2O5 Ga 2 O 5 0.00650.0065 SrOSrO 0.02550.0255 Y2O3 Y 2 O 3 0.00530.0053 ZrO2 ZrO 2 0.02650.0265 BaOBaO 0.05660.0566 ReO2 ReO 2 0.00650.0065 PbOPbO 0.00400.0040 TbO2 TbO 2 0.00230.0023 PaPa 0.02030.0203 total 100100

상기 본 발명에 따른 희토류 복합바이오광물질의 증류추출액은 상기 표 1의 성분으로 이루어진 원광을 분쇄한 후, 물을 첨가하여 증류냉각하여 얻어지는 것이다. 보다 구체적으로는 상기 희토류 복합바이오광물질을 물과 함께 증류기에 넣고 온도 110~130℃로 1~10시간 동안 가열한 후, 증류시켜 얻어진다.The distillate extract of the rare-earth complex bio-mineral material according to the present invention is obtained by pulverizing the ore composed of the components of Table 1, and then distilling and cooling the ore by adding water. More specifically, it is obtained by putting the rare earth complex biomineral together with water in a distiller and heating it at a temperature of 110 to 130° C. for 1 to 10 hours, followed by distillation.

상기 본 발명에 따른 희토류 복합바이오광물질의 증류추출액(이하, 「EF 21」로 칭한다)은 혈액순환을 촉진시켜 독소배출과 숙면에 도움을 주며, 특히 피부상태개선활성, 예를 들어 피부트러블의 원인이 되는 알러지, 특히 아토피에 대한 개선효과가 탁월하다.The distillation extract of the rare earth complex bio-mineral according to the present invention (hereinafter referred to as "EF 21") promotes blood circulation and helps to excrete toxins and sleep well, especially skin condition improvement activity, for example, a cause of skin troubles It is excellent in improving the allergy, especially atopy.

본 발명에 따른 피부외용제는 상기 EF 21 10~70중량%와 함께, 바람직하게는 피부트러블의 원인이 되는 알러지, 아토피에 대한 개선효과를 증진하기 위해 바람직하게는 어성초, 측백잎, 모려분, 유근피, 백선피, 및 지실에서 선택되는 적어도 1종의 증진제 혹은 이의 추출물을 각각 1~30 중량%, 보다 바람직하게는 어성초 1~30 중량%, 측백잎 1~20중량%, 모려분 1~10중량%, 유근피 1~10중량%, 백선피 1~10중량%, 및 지실 1~10중량%를 증류기에 투입하여 온도 110~130℃로 1~10시간 동안 가열하여, 증류시켜 얻어진 증진제를 포함하는 피부개선추출액을 0.1~99.9 중량% 포함한다.The external preparation for skin according to the present invention, together with 10 to 70% by weight of the EF 21, preferably, to promote the improvement effect on allergies and atopic dermatitis, which are the cause of skin troubles, preferably H. 1 to 30% by weight of each of at least one enhancer or an extract thereof selected from , white sagebrush, and oilseed oil, more preferably 1 to 30% by weight of Eoseongcho, 1 to 20% by weight of arborvitae leaf, 1 to 10% by weight of mulberry powder %, 1 to 10% by weight of Yugeun skin, 1 to 10% by weight of white sagebrush, and 1 to 10% by weight of oilseed oil are put in a distiller and heated at a temperature of 110 to 130° C. for 1 to 10 hours, containing an enhancer obtained by distillation Contains 0.1 to 99.9% by weight of the skin improvement extract.

상기 본 발명에 따른 피부외용제는 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The external preparation for skin according to the present invention may include components commonly used, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.

본 발명의 피부외용제는 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 수렴 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The external preparation for skin of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing , oil, powder foundation, emulsion foundation, wax foundation, spray, etc., but is not limited thereto. More specifically, it may be prepared in the form of a flexible lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.

본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide may be used as a carrier component. can

본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane /may contain propellants such as butane or dimethyl ether.

본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol fatty esters, fatty acid esters of polyethylene glycol or sorbitan.

본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Adult cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.

본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide as carrier components Ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester and the like can be used.

본 발명에 따른 피부외용제는 상기 각 활성성분 이외에 피부외용제의 제형에 있어서 통상적으로 사용될 수 있는 담체를 포함할 수 있다. 이러한 담체의 예로서는 알코올, 오일, 계면활성제, 지방산, 실리콘 오일, 습윤제, 보습제, 점성 변형제, 유제, 방부제, 안정제, 자외선 차단제, 발색제, 향료 등을 들 수 있다. 상기 담체는 본 발명의 피부외용제 전체 중량에 대하여 약 0.5 중량% 내지 약 99.99 중량%, 바람직하게는 조성물의 중량의 약 80 중량% 내지 약 99.99 중량%로 포함될 수 있다.The external preparation for skin according to the present invention may include, in addition to each of the above active ingredients, a carrier that can be commonly used in the formulation of external preparations for skin. Examples of such carriers include alcohols, oils, surfactants, fatty acids, silicone oils, humectants, humectants, viscosity modifiers, emulsifiers, preservatives, stabilizers, sunscreens, coloring agents, fragrances, and the like. The carrier may be included in an amount of from about 0.5% to about 99.99% by weight, preferably from about 80% to about 99.99% by weight of the weight of the composition, based on the total weight of the external preparation for skin of the present invention.

또한 본 발명에 따른 피부알러지 개선효과를 가지는 피부외용제는 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.In addition, the external preparation for skin having an allergy-improving effect according to the present invention can be used according to a conventional method of use, and the number of times of use can be varied according to the skin condition or taste of the user.

이하 본 발명의 내용을 실시예에 의해 보다 구체적으로 설명하기로 한다. 다만 이들 실시예 및 실험예는 본 발명의 이해를 위해 예시되는 것일 뿐 본 발명의 권리범위를 제한하지는 아니함을 유의해야 한다.Hereinafter, the contents of the present invention will be described in more detail by way of examples. However, it should be noted that these Examples and Experimental Examples are only illustrative for the understanding of the present invention and do not limit the scope of the present invention.

[실시예] 피부개선추출액의 조제[Example] Preparation of skin improvement extract

상기 표 1의 조성을 갖는 희토류 복합바이오광물질의 분말 5kg을 물 20리터와 함께 증류기에 넣고 온도 130℃로 5시간 동안 증류하여 추출액 EF 21을 얻었다. 5 kg of the powder of the rare earth complex bio-mineral having the composition of Table 1 was put in a distiller together with 20 liters of water and distilled at a temperature of 130° C. for 5 hours to obtain an extract EF 21.

그런 다음 상기 EF 21 50 중량%와 함께, 어성초 15 중량%, 측백잎 10중량%, 모려분 8중량%, 유근피 7중량%, 백선피 5중량%, 및 지실 5중량%를 증류기에 투입하여 온도 130℃로 6시간 동안 가열하여, 증류시켜 본 발명의 피부개선추출액을 얻었다. Then, along with 50% by weight of the EF 21, 15% by weight of eoseongcho, 10% by weight of arborvitae leaf, 8% by weight of mulberry flour, 7% by weight of Yugeun skin, 5% by weight of white sagebrush, and 5% by weight of oilseed oil were added to the distiller, and the temperature It was heated to 130° C. for 6 hours and distilled to obtain the skin improvement extract of the present invention.

[실시예 1] 연고의 제조[Example 1] Preparation of ointment

하기 표 2의 처방에 따라 공지된 방법에 의해 피부 외용 연고를 제조하였다.An ointment for external use on the skin was prepared by a known method according to the prescription in Table 2 below.

조성물composition 중량%weight% 피부개선추출액 skin improvement extract 4040 디에틸 세바케이트diethyl sebacate 88 경납brazing 55 폴리옥시에틸렌올레일에테르포스페이트Polyoxyethylene oleyl ether phosphate 66 벤조산 나트륨sodium benzoate 55 바셀린vaseline to 100to 100

[실시예 2] 크림의 제조[Example 2] Preparation of cream

하기 표 3의 처방에 따라 공지된 방법에 의해 크림을 제조하였다. Creams were prepared by a known method according to the prescription in Table 3 below.

조성물composition 중량%weight% 스테아린산stearic acid 1515 세탄올cetanol 1One 수산화칼륨potassium hydroxide 0.70.7 글리세린glycerin 55 프로필렌글리콜propylene glycol 33 방부제antiseptic 1One incense 1One 피부개선추출액skin improvement extract to 100to 100

[실시예 3] 화장수(미스트)의 제조[Example 3] Preparation of lotion (mist)

하기 표 4의 처방에 따라 공지된 방법에 의해 피부 외용 화장수를 제조하였다.A skin lotion for external use was prepared by a known method according to the prescription in Table 4 below.

조성물(중량%)Composition (wt%) 중량%weight% 폴리옥시에틸렌경화피마자유Polyoxyethylene hydrogenated castor oil 1.01.0 파라옥시안식향산메틸methyl paraoxybenzoate 0.20.2 글리세린glycerin 6.06.0 1,3-부틸렌글리콜1,3-butylene glycol 5.05.0 카보머Carbomer 0.20.2 트리에탄올아민triethanolamine 0.30.3 프로필렌글리콜propylene glycol 5.05.0 에탄올ethanol 3.23.2 카르복시비닐폴리머Carboxyvinyl Polymer 0.10.1 incense 적량appropriate amount 피부개선추출액skin improvement extract to 100to 100

[실험예 1] 연고, 크림의 피부 자극성 및 보호 효과 확인[Experimental Example 1] Confirmation of skin irritation and protective effect of ointment and cream

건강한 성인 남녀 20명(남자 10명, 여자 10명)의 전박부에 상기 각 실시예 1 및 실시예 2에서 제조한 외용제를 일정량(10m/5㎠)씩 도포하고, 그 외의 부위를 알루미늄 호일로 차폐하여 30분 후에, 자외선 조사기를 이용하여 장파장 자외선을 10.2J/㎠ 의 용량으로 조사하고 24시간 후에 피부 상태(홍반, 부종, 구진 등)를 관찰하였다. 관찰 결과 피부에 홍반 등의 부작용이 발생되지 않아 상기 각 외용제는 광독성이 없으며 피부 보호 효과가 있음을 확인할 수 있었다.A certain amount (10m/5cm2) of the external preparations prepared in Examples 1 and 2 above were applied to the forearms of 20 healthy adult males and females (10 males, 10 females), and the other areas were covered with aluminum foil. After 30 minutes of shielding, long-wavelength ultraviolet rays were irradiated with a dose of 10.2J/cm 2 using an ultraviolet irradiator, and skin conditions (erythema, edema, papules, etc.) were observed after 24 hours. As a result of observation, side effects such as erythema did not occur on the skin, so it was confirmed that each of the external preparations had no phototoxicity and had a skin protection effect.

[실험예 2] 화장수의 피부 자극성 및 보호 효과 확인[Experimental Example 2] Confirmation of skin irritation and protective effect of lotion

건강한 성인 남녀 20명(남자 10명, 여자 10명)의 전박부에 상기 실시예 3에서 제조한 화장수를 일정량(10m/5㎠)씩 도포하고, 그 외의 부위를 알루미늄 호일로 차폐하여 30분 후에, 자외선 조사기를 이용하여 장파장 자외선을 10.2J/㎠ 의 용량으로 조사하고 24시간 후에 피부 상태(홍반, 부종, 구진 등)를 관찰하였다. 관찰 결과 피부에 홍반 등의 부작용이 발생되지 않아 상기 화장수는 광독성이 없으며 피부 보호 효과가 있음을 확인할 수 있었다.Apply a certain amount (10m/5cm2) of the lotion prepared in Example 3 to the forearms of 20 healthy adult males and females (10 males, 10 females), and cover other areas with aluminum foil after 30 minutes , using a UV irradiator, long-wavelength UV light was irradiated at a dose of 10.2J/cm 2 , and skin conditions (erythema, edema, papule, etc.) were observed after 24 hours. As a result of observation, side effects such as erythema did not occur on the skin, so it was confirmed that the lotion had no phototoxicity and had a skin protection effect.

[실험예 3] 크림 및 화장수의 피부 안정성 확인 시험[Experimental Example 3] Skin stability test for cream and lotion

건강한 성인 남녀 20명(남자 10명, 여자 10명)의 전박부에 상기 각 실시예 1 및 실시예 3에서 제조한 외용제를 이용하여 인체 첩포 시험을 실시하였다. 시험대상자의 전박부를 70% 에탄올로 잘 닦은 다음 그 부위에, 통상의 화장료 기제에 상기 각 실시예에서 제조한 외용제를 20㎕씩 담은 핀 챔버를 점착 테이프를 이용하여 24시간 폐쇄 부착시켰다. 24시간 후에 점착 테이프와 핀 챔버를 제거하고, 가제로 피부에 잔존된 시료를 가볍게 닦아 제거한 뒤에 피부 상태를 관찰하고 다시 24시간 후에 한번 더 관찰하였다. 실험 결과 본 발명에 따른 외용제의 피부 자극성을 확인하기 위한 인체 첩포 시험에서 양성반응을 보이지 않아 인체 피부에 자극성이 전혀 없는 것으로 확인되었다.A human patch test was performed using the external preparations prepared in Examples 1 and 3 above on the forearms of 20 healthy adult males and females (10 males and 10 females). After wiping the forearm of the test subject well with 70% ethanol, a pin chamber containing 20 μl of the external preparations prepared in each example above in a conventional cosmetic base was closed and attached to the site for 24 hours using an adhesive tape. After 24 hours, the adhesive tape and the pin chamber were removed, and the sample remaining on the skin was lightly wiped off with gauze to observe the skin condition, and then again after 24 hours. As a result of the experiment, there was no positive reaction in the human patch test for confirming the skin irritation of the external preparation according to the present invention, so it was confirmed that there is no irritation to the human skin.

[실험예 4] 피부 알러지 개선 시험[Experimental Example 4] Skin allergy improvement test

피부 알러지 개선시험은 공지된 방법에 따라 NC/Nga 암컷 마우스 6주령을 이용하여 각 실시예의 가려움 억제 효과를 확인하였다. 이를 위해 1 주일 간의 순화기간을 거친 NC/Nga 마우스의 등을 제모한 후, 1-클로로-2,4-다이나이트로벤젠(DNCB, 알러지 유발제) 100 ㎕를(1 %, 용매는 아세톤:올리브오일=3:1) 5 일간 도포하여 알러지 감작 반응을 유도하였다. 이후, 4 주일 동안 1 일 1 회씩 0.4 % DNCB와 각 실시예 1 내지 3의 외용제를 처리하였다. 음성 대조군으로는 용매(아세톤:올리브오일=3:1) 100 ㎕를 도포하였으며, 양성 대조군으로는 글루코코티코스테로이드를 사용하였다. 또한, 군당 동물 개체수는 5 마리로 하였다. 가려움 억제 평가는 시료 처리 4 주 종료 시점에 DNCB 처리 직후, 무인 상태에서 뒷발로 긁는 횟수를 1시간 동안 비디오카메라로 녹화하여 횟수의 억제 정도로 평가하였다.The skin allergy improvement test confirmed the itch suppression effect of each example using a 6-week-old NC/Nga female mouse according to a known method. For this, after hair removal of the back of NC/Nga mice that have undergone a one-week acclimatization period, 100 μl of 1-chloro-2,4-dinitrobenzene (DNCB, allergen) (1%, solvent is acetone:olive) Oil = 3:1) was applied for 5 days to induce an allergic reaction. Thereafter, 0.4% DNCB and the external preparations of Examples 1 to 3 were treated once a day for 4 weeks. As a negative control, 100 μl of a solvent (acetone:olive oil=3:1) was applied, and as a positive control, a glucocorticosteroid was used. In addition, the number of animals per group was set to 5 animals. In the evaluation of itch suppression, immediately after DNCB treatment at the end of 4 weeks of sample treatment, the number of times of scratching with the hind paw in an unattended state was recorded with a video camera for 1 hour, and the degree of inhibition of the number of times was evaluated.

Figure pat00001
Figure pat00001

하기 표 5는 각 실시예의 외용제에 의한 가려움 억제효과(%)를 나타낸 것이다(n=5).Table 5 below shows the itch inhibitory effect (%) by the external preparation of each Example (n = 5).

성분ingredient 억제효과(%)Inhibitory effect (%) 실시예 1Example 1 8484 실시예 2Example 2 8787 실시예 3Example 3 9090 글루코코르티코스테로이드glucocorticosteroids 8686 대조군control --

[실험예 5] 아토피 증상완화 실험[Experimental Example 5] Atopic symptom relief experiment

피시험자로 아토피 질환을 갖고 있는 환자 70명을 대상으로 1주 동안 1일 2회씩 실시예 1 내지 3 및 비교예 1에 따라 제조된 기제를 이용하여 피부에 도포하였다. 각각에 대하여 실시예와 비교예를 육안으로 판정하고, 실시예가 비교예에 비해 증상완화 효과가 있는 정도를 효과있음, 차이없음의 2단계로 평가하였으며, 그 결과는 표 6과 같다.As a test subject, 70 patients with atopic disease were applied to the skin using the bases prepared according to Examples 1 to 3 and Comparative Example 1 twice a day for 1 week. For each, Examples and Comparative Examples were visually judged, and the degree of symptom relieving effect of the Example compared to the Comparative Example was evaluated in two stages: effective and no difference, and the results are shown in Table 6.

실험물질test substance 효과 있음(명)Effective (persons) 차이없음(명)No difference (persons) 실시예 1Example 1 77 33 실시예 2Example 2 77 33 실시예 3Example 3 88 22 비교예 1Comparative Example 1 00 1010

상기 표 5의 결과에서 볼 수 있듯이, 실시예 1 내지 3의 피부외용제는 각 실시예 당 피시험자 10명 중에서 최소 7명에 대하여 아토피 증상완화 효과를 나타내었으며, 피부 내에서 어떤 부작용도 나타나지 않은 것으로 나타났다.As can be seen from the results of Table 5, the external skin preparations of Examples 1 to 3 showed an atopic symptom relief effect for at least 7 of 10 test subjects per each Example, and no side effects were observed in the skin. appear.

상기와 같이, 본 발명의 바람직한 실시 예를 참조하여 설명하였지만 해당 기술 분야의 숙련된 당업자라면 하기의 특허청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.As described above, although described with reference to preferred embodiments of the present invention, those skilled in the art can variously modify and change the present invention within the scope without departing from the spirit and scope of the present invention described in the claims below. You will understand that it can be done.

Claims (6)

희토류 복합바이오광물질의 증류추출액을 활성성분으로 함유하는 피부외용제 조성물.A composition for external application for skin containing a distillate extract of rare earth complex bio-minerals as an active ingredient. 제 1항에 있어서,
상기 희토류 복합바이오광물질은 F 0.1~0.2중량%, Na2O 0.1~0.2중량%, MgO 0.08~0.09중량%, Al2O3 34.0~35.0중량%, SiO2 58.0~59.0중량%, P2O5 0.04~0.05중량%, SO3 0.01~0.02중량%, Cl 0.003~0.004중량%, K2O 2.8~2.9중량%, CaO 0.008~0.009중량%, TiO2 1.5~1.6중량%, Cr2O3 0.01~0.02중량%, MnO 0.01~0.02중량%, Fe2O3 1.0~2.0중량%, NiO 0.005~0.006중량%, CuO 0.002~0.003중량%, Ga2O5 0.006~0.007중량%, SrO 0.02~0.03중량%, Y2O3 0.005~0.006중량%, ZrO2 0.02~0.03중량%, BaO 0.05~0.06중량%, ReO2 0.006~0.007중량%, PbO 0.004~0.005중량%, TbO2 0.002~0.003중량%, Pa 0.02~0.03중량%를 포함하는 것을 특징으로 하는 피부외용제 조성물.
The method of claim 1,
The rare earth composite bio-mineral material is F 0.1 to 0.2 wt%, Na 2 O 0.1 to 0.2 wt%, MgO 0.08 to 0.09 wt%, Al 2 O 3 34.0 to 35.0 wt%, SiO 2 58.0 to 59.0 wt%, P 2 O 5 0.04~0.05 wt%, SO 3 0.01~0.02 wt%, Cl 0.003~0.004 wt%, K 2 O 2.8~2.9 wt%, CaO 0.008~0.009 wt%, TiO 2 1.5~1.6 wt%, Cr 2 O 3 0.01 to 0.02 wt%, MnO 0.01 to 0.02 wt%, Fe 2 O 3 1.0 to 2.0 wt%, NiO 0.005 to 0.006 wt%, CuO 0.002 to 0.003 wt%, Ga 2 O 5 0.006 to 0.007 wt%, SrO 0.02 to 0.03 wt%, Y 2 O 3 0.005 to 0.006 wt%, ZrO 2 0.02 to 0.03 wt%, BaO 0.05 to 0.06 wt%, ReO 2 0.006 to 0.007 wt%, PbO 0.004 to 0.005 wt%, TbO 2 0.002 to 0.003 wt% %, Pa composition for external application for skin, characterized in that it comprises 0.02 to 0.03% by weight.
제 1항에 있어서, 상기 증류추출액은,
상기 희토류 복합바이오광물질을 물과 함께 증류기에 넣고 온도 110~130℃로 1~10시간 동안 가열한 후, 증류시켜 얻어진 것을 특징으로 하는 피부외용제 조성물.
According to claim 1, wherein the distillate extract,
The composition for external application for skin, characterized in that it is obtained by putting the rare earth complex bio-mineral together with water in a distiller, heating it at a temperature of 110 to 130° C. for 1 to 10 hours, and then distilling it.
제 1항에 있어서,
상기 증류추출액과 함께 어성초, 측백잎, 모려분, 유근피, 백선피, 및 지실의 증류추출액을 더 포함하는 것을 특징으로 하는 피부외용제 조성물.
The method of claim 1,
The composition for external application for skin, characterized in that it further comprises a distillate extract of eoseongcho, chrysanthemum leaves, moryu powder, eugeunpi, baekseonpi, and lichen together with the distillate extract.
제 4항에 있어서,
상기 증류추출액 20~70중량%, 어성초 1~30 중량%, 측백잎 1~20중량%, 모려분 1~10중량%, 유근피 1~10중량%, 백선피 1~10중량%, 및 지실 1~10중량%를 증류기에 투입하여 증류시켜 얻어진 피부개선추출액을 포함하는 것을 특징으로 하는 피부외용제 조성물.
5. The method of claim 4,
20 to 70% by weight of the distillation extract, 1 to 30% by weight of Eoseongcho, 1 to 20% by weight of chrysanthemum leaves, 1 to 10% by weight of mulberry flour, 1 to 10% by weight of Yugeun skin, 1 to 10% by weight of white sagebrush, and 1 A composition for external application for skin, comprising a skin improvement extract obtained by distilling ~10% by weight in a distiller.
제 1항 내지 제 4항 중 선택된 어느 하나에 있어서,
피부외용제는 아토피 치료용 조성물인 것을 특징으로 하는 피부외용제 조성물.
5. The method according to any one of claims 1 to 4,
The composition for external application for skin is a composition for the treatment of atopic dermatitis.
KR1020210000852A 2021-01-05 2021-01-05 Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy KR20220098938A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020210000852A KR20220098938A (en) 2021-01-05 2021-01-05 Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020210000852A KR20220098938A (en) 2021-01-05 2021-01-05 Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy

Publications (1)

Publication Number Publication Date
KR20220098938A true KR20220098938A (en) 2022-07-12

Family

ID=82419845

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020210000852A KR20220098938A (en) 2021-01-05 2021-01-05 Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy

Country Status (1)

Country Link
KR (1) KR20220098938A (en)

Similar Documents

Publication Publication Date Title
DK2498783T3 (en) COMPOSITIONS AND PROCEDURES FOR STIMULATING HAIR GROWTH
KR101860496B1 (en) Composition containing extract of venus flytrap for cosmetic treatment
KR101987903B1 (en) Cosmetic composition for treating atopic dermatitis and method thereof
KR101339096B1 (en) Skin lightening composition for hyperpigmented skin
KR20200114029A (en) Skin moisturizing and skin soothing cosmetic composition comprising Aloe barbadensis leaf juice and extracts of Pulsatilla koreana, Centella asiatica, Portulaca oleracea and Hamamelis virginiana
KR102142311B1 (en) Skin external composition comprising tangeretin
JP4398641B2 (en) Hypoallergenic and non-irritating skin care preparations
US20040101577A1 (en) Composition for treating acne vulgaris and fabrication method
EP1762241A1 (en) Compositions and methods for mitigating skin irritation
KR100702327B1 (en) Cosmetic material including extract of camellia flower for skin abirritation
JPH08133952A (en) Skin preparation for external use
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
KR100879094B1 (en) Cosmetics formulation containing natural essential oils and its hydrosols
KR100754748B1 (en) Compositiion for Inhibiting 5?-Reductase Activity and Cosmetic Composition for Inhibiting Secretion of Sebum containing Extract of Ulmus davidiana as Active Ingredient
KR100638053B1 (en) Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient
KR102102041B1 (en) Cosmetic composition for skin soothing containing complex extracts of Hamamelis virginiana, Centella asiatica and Boswellia serrata resin, and mask-pack comprising the same
KR102058294B1 (en) Cosmetic composition for skin regenerating containing complex extracts of snail mucus, Boswellia serrata resin and Aloe barbadensis leaf, and cream comprising the same
JPH10158148A (en) Skin-whitening cosmetic
KR102217697B1 (en) Aromatherapy composition comprising natural aroma oil
KR20220098938A (en) Skin external composition comprising distilled extract of rare earth complexbiomineral for alleviating skin allergy
KR100816265B1 (en) Cosmetic Composition for Abirritating Skin Containing Extract of Rheum undulatum as Active Ingredient
KR20220001161A (en) Composition for skin protection, including extracts derived from natural products
KR20130103199A (en) Composition for preventing sleeping drive
JPH03200708A (en) Dermal external agent
KR101322850B1 (en) The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum

Legal Events

Date Code Title Description
E90F Notification of reason for final refusal